


CJC-1295 & IPA
$36.00
CJC-1295 & Ipamorelin (CJC/IPA Blend) is a research peptide combination containing CJC-1295 (a 29-amino acid modified GHRH analog) and Ipamorelin (a 5-amino acid selective growth hormone secretagogue pentapeptide).
CJC-1295 was developed in the early 2000s by ConjuChem Biotechnologies. Ipamorelin was developed in the mid-1990s by Novo Nordisk A/S.
The blend itself is a modern research formulation created by specialty peptide laboratories.
Researchers have investigated this combination in preclinical and early clinical models for its synergistic ability to stimulate pulsatile and sustained endogenous growth hormone release from the pituitary gland.
Primary areas of study include growth hormone deficiency models, body composition (lean mass and fat reduction), metabolic parameters, recovery, and endocrine research. The dual mechanism (GHRH pathway + ghrelin receptor mimicry) is explored for amplified yet physiologic GH pulses.
